What are the diagnostic criteria for Creutzfeldt-Jakob disease (CJD)?

Diagnostic Criteria for Creutzfeldt-Jakob Disease

The diagnosis of sporadic CJD requires rapidly progressive dementia plus at least two clinical features (myoclonus, visual/cerebellar dysfunction, pyramidal/extrapyramidal signs, akinetic mutism) combined with positive biomarkers: either MRI showing cortical ribboning/high signal in ≥2 cortical regions OR caudate/putamen involvement on DWI/FLAIR, positive CSF RT-QuIC (if available), or periodic sharp wave complexes on EEG. 1

Diagnostic Classification Framework

Definite CJD

• Neuropathologically confirmed with PrPSc deposition on brain biopsy or autopsy 2
• Immunohistochemistry with anti-prion protein antibodies is the gold standard diagnostic technique 2

Probable CJD (Amended WHO Criteria)

Clinical syndrome PLUS positive biomarkers:

Clinical Requirements:

• Rapidly progressive dementia (primary feature)
• At least two of the following:
  • Myoclonus
  • Visual or cerebellar dysfunction
  • Pyramidal or extrapyramidal signs
  • Akinetic mutism 1

Biomarker Requirements (any one of):

1. MRI findings (highest specificity when interpreted by experienced raters):

   • High signal on DWI or FLAIR in ≥2 cortical regions (temporal, parietal, or occipital), OR
   • High signal in both caudate nucleus AND putamen 3
   • Sensitivity: 83-92%, Specificity: 81-87% 4, 3
   • Critical point: DWI sequences are superior to FLAIR for detecting abnormalities 1

2. CSF RT-QuIC (when available - now the most sensitive test):

   • Sensitivity: 92-96%, Specificity: 99-100% 1, 4
   • Should be performed in every suspected case 1
   • Can be positive even when clinical criteria incomplete 1

3. CSF 14-3-3 protein (primary CSF surrogate marker):

   • Cut-off: >20,000 AU/mL 1
   • Less sensitive in early disease and certain subtypes 1

4. EEG showing periodic sharp wave complexes (PSWCs) 1

   • May appear later in disease course 1

Supportive CSF biomarkers:

• Total tau (t-Tau) >1,300 pg/mL 1
• p-Tau/t-Tau ratio (or inverse) 1

Possible CJD

• Rapidly progressive dementia with clinical features but no positive biomarkers
• Only diagnose after extensive workup excludes alternative causes 1

Essential Diagnostic Workup

Minimum required investigations 1:

• Clinical neurological examination
• Blood sampling (exclude metabolic/inflammatory causes)
• Lumbar puncture with CSF analysis
• Brain MRI with specific sequences: T1 with contrast, FLAIR, DWI with ADC maps 1
• EEG
• PRNP gene sequencing (exclude genetic CJD, assess codon 129 polymorphism) 1

Critical Diagnostic Nuances

Timing considerations:

• All biomarkers have reduced sensitivity in early disease stages 1
• Follow-up investigations may be necessary if initial tests negative 1
• RT-QuIC can remain positive even when other markers are equivocal 1

Atypical presentations:

• Some molecular subtypes (e.g., MM2C "cortical" subtype) may show only rapidly progressive dementia without full clinical syndrome 1
• In these cases, positive RT-QuIC can establish probable diagnosis despite incomplete clinical criteria 1
• Disease duration varies: typical cases 2-4 months, atypical cases up to 11+ months 1

Common Diagnostic Pitfalls

Conditions that mimic CJD biomarkers 1:

• Autoimmune/immune-mediated encephalitis
• Status epilepticus
• Cerebral ischemia
• Other rapidly progressive neurodegenerative diseases

How to avoid misdiagnosis:

• Exclude CNS inflammation in CSF analysis 1
• Perform PRNP sequencing to rule out genetic CJD (gCJD) 1
• Consider iatrogenic CJD (iCJD) and variant CJD (vCJD) based on clinical indicators 1
• Ensure MRI interpretation by experienced raters (inter-rater reliability is only moderate) 5

When to Consider Brain Biopsy

Brain biopsy is invasive but can be considered when:

• Non-invasive diagnostics remain inconclusive, AND
• A potentially treatable alternative diagnosis is suspected 1

Key laboratory requirement: All biomarker testing must be performed in experienced and certified laboratories 1